|
|
|
|
|
Pathogenesis of Pulmonary Cryptococcus gattii Infection: A Rat Model |
2553 |
# |
|
|
|
|
|
Pathogenesis of the H5N1 avian influenza virus in humans and mammalian models |
2552 |
# |
|
|
|
|
|
Pathogenic organisms and prognostic factors of visual outcome in endogenous endophthalmitis |
2561 |
# |
|
|
|
|
|
Pathogenic PSEN1 Glu184Gly mutation in a family from Thailand with probable autosomal dominant early onset Alzheimer’s disease |
2563 |
# |
|
|
|
|
|
Pathogenic Variants in the Myosin Chaperone UNC-45B Cause Progressive Myopathy with Eccentric Cores |
2563 |
# |
|
|
|
|
|
Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy |
2555 |
# |
|
|
|
|
|
Pathologic findings in cadaveric-donor transplanted kidney with delayed graft function and their correlation with allograft outcome |
2555 |
# |
|
|
|
|
|
Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar |
2557 |
# |
|
|
|
|
|
Pathologic Risk Factors and Oncologic Outcomes in Early-stage Cervical Cancer Patients Treated by Radical Hysterectomy and Pelvic Lymphadenectomy at a Thai University Hospital: A 7 year Retrospective Review. |
2558 |
# |
|
|
|
|
|
PATHOLOGICAL COMPLETE RESPONSE TO TRASTUZUMAB SUBCUTANEOUS FIXED-DOSE FORMULATION IN THE HANNAH STUDY: SUBGROUP ANALYSIS OF PATIENT DEMOGRAPHICS AND TUMOR CHARACTERISTICS AND INFLUENCE OF BODY WEIGHT (BW) AND SERUM TROUGH CONCENTRATION (CTROUGH) OF T |
2555 |
# |
|
|
|
|
|
Pathological Crying After Subthalamic Nucleus Stimulation |
2556 |
# |
|
|
|
|
|
Pathological discrepancy between colposcopic directed cervical biopsy and Loop Electrosurgical-Excision Procedures (LEEPs) in patients with biopsies proven high grade cervical intraepithelial neoplasia. |
2560 |
# |
|
|
|
|
|
Pathologically different features and fibrosis scores in chronic hepatitis C genotypes 3 and 1. |
2550 |
# |
|
|
|
|
|
Pathology and etiology of 110 consecutively removed aortic valves. |
2547 |
# |
|
|
|
|
|
Pathology of fatal diffuse brain injury in severe non-penetrating head trauma |
2564 |
# |
|
|
|
|
|
Pathology of pythium arteritis |
2553 |
# |
|
|
|
|
|
Pathophysiologic studies of rabies in dogs and role of artificial microRNA in inhibiting viral replication (The Eddie and Piloo Bharucha Lecture) |
2552 |
# |
|
|
|
|
|
Patient characteristics and critical care workflow affect paging frequency in neurocritical care |
2561 |
# |
|
|
|
|
|
Patient characteristics, clinical manifestations, prognosis, and factors associated with gastrointestinal cytomegalovirus infection in immunocompetent patients |
2563 |
# |
|
|
|
|
|
Patient dosimetry of Lu-177-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand |
2564 |
# |
|
|
|
|
|
Patient expectations for health supervision advice in continuity clinic: Experience from a teaching hospital in Thailand |
2556 |
# |
|
|
|
|
|
Patient interviews improve empathy levels of preclinical medical students |
2562 |
# |
|
|
|
|
|
Patient preference and sensory perception of three intranasal corticosteroids for allergic rhinitis. |
2546 |
# |
|
|
|
|
|
Patient Recovery from COVID-19 Infections: Follow-Up of Hair, Nail, and Cutaneous Manifestations |
2564 |
# |
|
|
|
|
|
Patient reported hypoglycemic symptoms among Asian patients with Type 2 diabetes receiving oral anti-hyperglycemic agents |
2551 |
# |
|
|
|
|
|
PATIENT REPORTED OUTCOMES (PROS) OF MULTIPLE MYELOMA (MM) PATIENTS FROM THE PANORAMA-1 STUDY WHO HAVE RECEIVED AT LEAST TWO PRIOR REGIMENS INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT |
2559 |
# |
|
|
|
|
|
Patient Reports from ADAURA: HRQol Data on Osimertinib as adjuvant Therapy in Patients with resected EGFR-mutated (EGFRm) NSCLC |
2564 |
# |
|
|
|
|
|
Patient satisfaction, quality of life and outcomes of delayed postmastectomy breast reconstruction in early breast cancer patient: a tertiary care center |
2560 |
# |
|
|
|
|
|
Patient-based transcriptome-wide analysis identify interferon and ubiquination pathways as potential predictors of influenza a disease severity. |
2557 |
# |
|
|
|
|
|
Patient-ready syringes containing 25 mg/mL methotrexate can be kept at temperature ranging from 4 °C to 37 °C for up to 12 weeks for use in psoriatic and rheumatologic conditions |
2563 |
# |